Independent
Tenure on this board
5.3 yrs
Meeting calendar
ETON · Annual meeting · Tuesday, June 9, 2026
Eton Pharmaceuticals Inc
5 nominees · 2 ballot items.
Elect two Class II directors; ratify appointment of Grant Thornton LLP as independent auditors for fiscal year ending December 31, 2026; transact any other business properly brought before the meeting.
Market cap
$1.2B
1Y TSR
+145.1%
Board grade
B-
Record date
Apr 10, 2026
Filing
DEF 14A
Meeting concluded · Jun 9, 2026
Follow how the vote landed and what changed on Eton Pharmaceuticals Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORElect Jenn Adams and Charles J. Casamento as Class II directors to serve three-year terms until the 2029 annual meeting or until their successors are elected and qualified.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Grant Thornton LLP as the company’s independent registered public accounting firm for fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot5
Independent
Tenure on this board
9.1 yrs
Also a director at
Relmada Therapeutics Inc (RLMD)Gt Biopharma Inc (GTBP)
Independent
Tenure on this board
8.9 yrs
Also a director at
Jazz Pharmaceuticals PLC (JAZZ)
Not independent
Tenure on this board
9.1 yrs
Independent
Tenure on this board
8.9 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Opaleye Management Inc. | 10.4% | 2,860,000 | $71M |
| 2 | EcoR1 Capital, LLC | 7.9% | 2,171,938 | $54M |
| 3 | Nantahala Capital Management, LLC | 4.3% | 1,175,951 | $29M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 994,089 | $25M |
| 5 | BlackRock, Inc. | 3.5% | 956,680 | $24M |
| 6 | BlackRock, Inc. | 2.2% | 594,034 | $15M |
| 7 | STATE STREET CORP | 1.9% | 530,215 | $13M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 493,384 | $12M |
| 9 | National Philanthropic Trust | 1.8% | 492,112 | $12M |
| 10 | Westside Investment Management, Inc. | 1.7% | 467,915 | $12M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Eton Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Reference
Frequently asked questions
- When is the Eton Pharmaceuticals Inc 2026 annual meeting?
- Eton Pharmaceuticals Inc (ETON) holds its 2026 annual shareholder meeting on Tuesday, June 9, 2026.
- What is the record date for the Eton Pharmaceuticals Inc 2026 meeting?
- The record date for the Eton Pharmaceuticals Inc 2026 meeting is Friday, April 10, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Eton Pharmaceuticals Inc's 2026 meeting?
- The board is presenting 5 director nominees at the Eton Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Eton Pharmaceuticals Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Eton Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.